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Introduction
Advances over the last few decades have demon-
strated the autoimmune nature of multiple sclero-
sis (MS) and the role of immune cell subsets in 
disease development and progression.1 Much of 
what is known about the involvement of the 
immune system in MS is derived from studies in 
patients with moderately advanced relapsing–
remitting multiple sclerosis (RRMS). In contrast, 
less is known about the role of the immune sys-
tem in patients with clinically isolated syndrome 
(CIS), the earliest clinical MS phenotype. While 
it is conceivable that there are no or only minor 
biological differences between the initial and sub-
sequent clinical MS events, it is relevant to study 
the involvement of immune cell types in CIS in 
order to understand their contribution in conver-
sion from CIS to RRMS.2 Variation in clinical 
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Abstract
Background: Cladribine tablets 3.5 mg/kg cumulative over 2 years (CT3.5) had significant 
clinical/imaging effects in patients with clinically isolated syndrome (CIS; ORACLE-MS) or 
relapsing-remitting MS (RRMS; CLARITY and CLARITY Extension). This analysis compared 
the effect of cladribine tablets on the dynamics of immune cell reduction and reconstitution in 
ORACLE-MS, CLARITY, and CLARITY Extension during the first year of treatment (i.e. the first 
course of CT1.75) in patients randomized to CT3.5.
Methods: Lymphocyte subtypes were analyzed using multiparameter flow cytometry. Changes 
in cell counts and relative proportions of lymphocytes were evaluated at weeks 5, 13, 24, and 
48.
Results: Across studies, consistent and comparable selective kinetics of immune cell 
populations occurred following the first treatment year with CT. A rapid reduction in CD16+/
CD56+ cells (week 5 nadir), a more marked reduction in CD19+ B cells (week 13 nadir), and 
a less-pronounced effect on CD4+ (week 13 nadir) and CD8+ T cells (week 24 nadir) was 
shown. There was little effect on neutrophils or monocytes. Lymphocyte recovery began 
after treatment with CT3.5. Regarding relative proportions of naïve and memory T-cell 
subtypes in ORACLE-MS, the proportion of naïve-like naturally occurring T-regulatory cells 
(nTregs) decreased, and the proportion of memory-like nTregs increased, relative to total 
CD4+ T cells.
Conclusions: CT3.5 has comparable effects on the immune systems of patients with CIS 
or RRMS. The pronounced reduction and recovery dynamics of CD19+ B cells and relative 
changes in the proportion of some immune cell subtypes may underlie the clinical effects of 
CT3.5.
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response may potentially indicate differences in 
immune cell populations in CIS and RRMS. In 
patients with CIS, early treatment with disease-
modifying therapies (DMTs) has been shown to 
delay the time of conversion to clinically definite 
MS and to slow the progression of disability.3 In 
patients with RRMS, earlier treatment, as well as 
a longer duration of treatment, has been associ-
ated with delayed conversion to secondary pro-
gressive MS.4 It should be noted that the terms 
CIS and first clinical demyelinating event (used 
in some publications) are typically used inter-
changeably and describe the same presentation. 
Therefore, these terms are considered equivalent 
herein.
In RRMS, the involvement of immune cell sub-
types has been studied extensively, including the 
role of B and T lymphocytes and subtypes.5 In 
patients with CIS, the role of immune cell sub-
types has been investigated to a lesser degree, 
although decreases in CD4+ T lymphocytes and 
CD19+ B lymphocytes have been associated with 
disease worsening.6 Assessment of the speed and 
nature of lymphocyte reduction and reconstitu-
tion may help to further shed light on the role of 
specific immune cell subpopulations on disease 
activity (magnetic resonance imaging [MRI] 
activity, relapses, or disability worsening). 
Immune reconstitution therapy (IRT) is charac-
terized by transient effects on lymphocyte counts 
or lymphocyte subtype populations. This is fol-
lowed by a period of recovering cell numbers with 
reconstitution of immune function and durable 
efficacy beyond the initial immunosuppression.7 
An IRT that selectively targets B and T cells, 
without significant impact on innate immunity or 
induction of secondary autoimmunity through 
impaired immune homeostasis, would be of con-
siderable interest for the treatment of MS.7,8
Cladribine tablets 10 mg (MAVENCLAD) were 
recently approved for the treatment of active 
RRMS in Europe and other countries and 
regions. The approved indication in Europe is a 
cumulative dose of cladribine tablets 3.5 mg/kg 
(CT3.5) over 2 years for the treatment of adult 
patients with highly active relapsing MS as 
defined by clinical or imaging features. In patients 
with active RRMS, the CLARITY study showed 
that 2 years’ treatment, given as a first short 
course of CT1.75 at the beginning of the first 
year (Year 1) followed by a second short course 
of CT1.75 at the beginning of the second year 
(Year 2) with a cumulative dose of CT3.5, was 
effective on clinical and neurological out-
comes.9–11 Durable clinical and imaging benefits 
were observed in the 2-year CLARITY Extension 
study, in the group of patients who received no 
additional active treatment following 2 years of 
treatment in CLARITY.12,13 Cladribine tablets 
are not approved for patients with CIS. In the 
2-year ORACLE-MS study, treatment with 
CT3.5 significantly delayed time to conversion 
to clinically definite MS in patients presenting 
with CIS.14 Subgroup analyses in patients retro-
spectively classified according to whether or not 
they met the 2010 McDonald criteria for MS 
also demonstrated efficacy, consistent with the 
main study findings.15
The effects of CT3.5 in CLARITY have been 
assessed for several immune cell types, including 
mature CD19+ B cells, as well as several naïve 
and memory CD4+ and CD8+ T-lymphocyte 
subtypes and CD16+/56+ natural killer (NK) 
cells. That analysis found that CT treatment pro-
duced marked reductions in B cells from baseline 
(70–90%), and more modest reductions in T cells 
(up to 45%) and NK cells (47%).16 Naïve T cells 
and memory T cells displayed similar reduction 
and recovery kinetics, albeit with a marginally 
more modest effect on the memory T cells 
(CD45RA-) than the naïve T cells (CD45RA+).16 
Furthermore, a recent study with parenteral clad-
ribine has suggested that the large reductions in B 
cells was characterized by marked reductions in 
memory B cells.17
Investigating the effects of CT treatment in 
ORACLE-MS provides an opportunity to analyze 
the dynamics of reduction and reconstitution of 
immune cell subtypes in patients with CIS and to 
compare those dynamics with an RRMS popula-
tion. The objective of the present analysis is to 
compare reduction and reconstitution of CD19+ B 
cells, memory and naïve CD4+ and CD8+ T cells, 
NK cells, neutrophils, and monocytes after the first 
of the two annual treatment courses of CT in 
patients with CIS versus patients with established 
MS receiving placebo or a first course of CT3.5 as 
part of one of the three clinical trials (CLARITY, 
CLARITY Extension, and ORACLE-MS). In 
addition, the analysis assessed an extended surface 
marker panel of T-lymphocyte subtypes in 
ORACLE-MS using fluorescence-activated cell 
sorting (FACS). This panel includes central and 
effector memory CD4+ cells, Th1-type T-helper 
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cells, and naïve and memory naturally occurring 
regulatory T cells (nTregs), which have not previ-
ously been assessed in patients with CIS treated 
with cladribine tablets.
Methods
ORACLE-MS, CLARITY, and CLARITY 
Extension were undertaken in compliance with 
the Declaration of Helsinki and standards of 
Good Clinical Practice according to the 
International Conference on Harmonisation of 
Technical Requirements for Registration of 
Pharmaceuticals for Human Use. Independent 
ethics committees approved the studies and all 
patients gave written informed consent before 
screening.
ORACLE-MS
The phase III ORACLE-MS study (ClinicalTrials.
gov identifier: NCT00725985) has been described 
previously. Briefly, patients with CIS (n = 617) 
were randomized (1:1:1) to 96 weeks (2 years) of 
double-blind treatment with placebo, a cumula-
tive dose of CT3.5 or CT 5.25 mg/kg bodyweight 
(CT5.25).14 In the first year of the study, patients 
randomized to the CT3.5 treatment arm received 
two short (4 or 5 days) weekly treatments. The 
two weekly treatments were repeated in the sec-
ond year of the study. Therefore, patients received 
a total of 1.75 mg/kg of cladribine tablets in the 
first year (year 1). The first weekly treatment was 
at the beginning of the first month of the double-
blind period, and the second weekly treatment 
was at the start of the second month (this is con-
sistent with the approved dosing regimen in the 
Summary of Product Characteristics).18 The 
ORACLE-MS safety analysis set included all ran-
domized patients who received at least one dose 
of study medication and had at least one safety 
assessment during the initial treatment period.
CLARITY and CLARITY Extension
In the CLARITY study (ClinicalTrials.gov iden-
tifier: NCT00213135), patients with RRMS 
(n = 1326) were randomized (1:1:1) to receive 
either placebo or a cumulative dose of CT3.5 or 
CT5.25 over 2 years. Patients who completed 
CLARITY were eligible to enter the CLARITY 
Extension study (ClinicalTrials.gov identifier: 
NCT00641537; n = 806), in which patients on 
placebo during the CLARITY study were 
assigned CT3.5 for a further 2 years. Patients on 
CT during the CLARITY study were randomized 
to CT3.5 or placebo for the same duration. These 
studies have been described previously, including 
primary safety and efficacy outcomes.9,10,12,13,19,20 
In each of these studies, the dosing schedule was 
similar to that used in ORACLE-MS.
Lymphocytes and myeloid cells
Counts of lymphocytes, neutrophils, and mono-
cytes were assessed centrally in all randomized 
patients in ORACLE-MS, CLARITY, and 
CLARITY Extension. These analyses are of data 
collected during the first 48 weeks of each study 
(i.e. patients had received only the first year of the 
2-year treatment course). Samples were collected 
at baseline and weeks 2, 5, 9, 13, 16, 24, 36, 44, 
and 48 in ORACLE-MS, and at weeks 5, 9, 13, 
16, 20, 24, 36, 40, and 48 in CLARITY and 
CLARITY Extension.
Lymphocyte surface marker (LSM) analyses were 
restricted to patients randomized to treatment 
with placebo or CT3.5 who had signed an 
informed consent form specifically for the LSM 
analyses. Certain patients and time periods were 
excluded from the analyses due to study- 
site-related requirements, including the need for 
specific informed consent. Data gathered after 
week 48 in each study (to include the second year 
of the 2-year treatment course) are not included 
in the present analyses.
LSM analyses
The LSM set comprised all randomized patients 
who provided informed consent, received at least 
one dose of study drug (cladribine tablets or pla-
cebo) and who had at least one LSM assessment 
between baseline and the end of Year 1 (i.e. the 
Week 48 visit). Analyses were performed cen-
trally, using the as-treated principle.
In the ORACLE-MS study an extended panel of 
LSM was assessed via FACS. The markers 
included in the analysis of each of the three stud-
ies, and the extended panel of markers analyzed 
in ORACLE-MS only are listed in Supplementary 
Table 1. Analysis of LSM was carried out at day 
1 (baseline) and weeks 5, 13, 24, and 48. For 
each LSM, the median cell count, change from 
baseline, and the percentage change was sum-
marized descriptively at each time point. The 
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cell count for each marker was also assessed at 
absolute lymphocyte count (ALC) nadir. This 
was defined for each patient as the lowest post-
baseline value relative to their baseline ALC 
value up to the end of year 1. The change from 
baseline at ALC nadir (absolute cell numbers, 
change, and percentage change) was summa-
rized descriptively.
In addition to assessing changes in counts of lym-
phocyte subtypes, proportions of CD4+ and 
CD8+ T cells were calculated relative to ALC at 
each time point. Median proportions of CD4+ 
T-cell subtypes were measured relative to total 
CD4+ T-cell counts. Exceptions to this were 
naïve- and memory-like nTregs, which were 
measured relative to total nTreg counts.
Further detail on methods used for immunophe-
notyping is provided in the Supplementary 
Material. International reference ranges for lym-
phocyte subpopulations where available and as 
reported by the central laboratories are provided 
in Supplementary Table 2A and B.
Statistical analyses
All analyses of the year 1 LSM data should be con-
sidered as exploratory. Year 2 analyses were not 
conducted. The results are presented with no for-
mal statistical testing since the clinical studies were 
not powered to detect changes between each time-
point for each lymphocyte subset. Continuous 
variables were summarized using descriptive statis-
tics, including number of patients, number of 
patients with nonmissing values, mean, standard 
deviation, median, 25th percentile–75th percentile 
(Q1–Q3), minimum, and maximum. Qualitative 
variables were summarized by counts and percent-
ages. Unless otherwise stated, the calculation of 
proportions was based on the number of patients 
in the analysis set of interest.
Results
Patients
In ORACLE-MS, a total of 88 patients were 
included in the LSM analysis set: 47 received pla-
cebo and 41 received CT3.5. In the LSM set, the 
mean age was 31.7 years and 71.6% of patients 
were female; in the overall ORACLE-MS popula-
tion, the mean age was 31.9 years and 65% were 
female.14 The total lymphocyte count in the LSM 
analysis set (see below) was similar to the overall 
ORACLE-MS population (data not shown). The 
LSM analyses of CLARITY and CLARITY 
Extension included a total of 281 patients. In the 
CLARITY LSM set, 93 patients received placebo 
and 97 received CT3.5 (for a total of 190 
patients); in the CLARITY Extension LSM set, 
136 patients received CT3.5 (these patients had 
previously been treated with placebo during 
CLARITY). A total of 45 patients are common to 
the CLARITY and CLARITY Extension LSM 
sets (received placebo in CLARITY and CT3.5 
in CLARITY Extension). The mean age in the 
CLARITY and CLARITY Extension LSM sets 
was 38.6 and 39.7 years, respectively, and 64.7% 
and 61.8% of patients were female. For the over-
all CLARITY population the mean age was 
38.6 years and 67.7% of patients were female and 
at baseline of CLARITY Extension, the mean age 
was 41.1 years with 65.9% female patients.
ALCs
At baseline, the median ALC in the ORACLE-MS 
safety analysis set and the LSM analysis sets were 
similar. In the ORACLE-MS safety analysis set, 
the median baseline ALC was 1.92 × 109/l (Q1–
Q3 1.64–2.34) in patients treated with CT3.5 
(n = 206), and 1.89 × 109/l, Q1–Q3 1.63–2.35) 
in placebo recipients (n = 206). In the LSM anal-
ysis set, the median baseline ALC was 1.76 × 109/l 
(Q1–Q3 1.48–2.10) in the placebo group, and 
1.76 × 109/l, Q1–Q3 1.58–2.22) in the CT3.5 
group.
In patients treated with CT3.5, median ALC 
showed a rapid decline from baseline to week 2, 
which was maintained until week 5. A further 
decrease was observed after week 5, following the 
second treatment week; this decrease was fol-
lowed by gradual recovery (Figure 1). In patients 
treated with CT3.5, median time to lowest con-
centration point (nadir) was 106.0 days (Q1–Q3 
64.0–168.0), median ALC at nadir was 0.78 × 
109/l (Q1–Q3 0.62–0.99). For CLARITY and 
CLARITY Extension, longitudinal data on ALC 
have been published elsewhere.21 Patients who 
were randomized to placebo in CLARITY were 
assigned to CT3.5 in CLARITY Extension; 
patients who were randomized to CT3.5 in 
CLARITY were re-randomized to CT3.5 or pla-
cebo in CLARITY Extension.
O Stuve, PS Sorensen et al.
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Cell types analyzed in CLARITY, CLARITY 
Extension and ORACLE-MS
Natural killer cells (CD16+/CD56+). In each study, 
median counts of CD16+/CD56+ cells decreased 
rapidly from baseline to reach nadir at week 5. 
These represented changes from baseline of 
−43.9%, −30.1%, and −32.7% in CLARITY, 
CLARITY Extension, and ORACLE-MS, respec-
tively (Table 1 and Figure 2A and B). Recovery of 
CD16+/CD56+ was rapid in each study, and well 
advanced at week 24. The interquartile range 
(IQR) values for the placebo and CT3.5 groups in 
each study overlapped for the majority of the treat-
ment period timepoints and approached baseline 
counts at week 48.
B cells (CD19+). Changes in median CD19+ B-cell 
counts in patients treated with CT3.5 in CLAR-
ITY, CLARITY Extension, and ORACLE-MS 
were relatively rapid (approximately 70% reduc-
tion from baseline at week 5 in each study, Table 1 
and Figure 2C and D) and reached nadir at week 
13 in each study, with a decline of 81–84% from 
baseline. Median CD19+ B-cell counts recovered 
towards baseline after week 13, showing reduc-
tions of approximately 60% and 30% at week 24 
and 48, respectively. Further subsets of B lympho-
cytes were not analyzed in the CLARITY, CLAR-
ITY Extension, or ORACLE-MS studies.
T-helper cells (CD4+). The pattern of response to 
treatment with CT3.5 was similar across the 
three studies. Median counts of CD4+ T cells 
showed a slow decrease from baseline to nadir, 
followed by stabilization and a relatively minor 
recovery towards baseline: IQRs for the CT3.5 
and placebo groups did not overlap in any study 
at weeks 13 and 24, but did so at week 48. In 
CLARITY and in ORACLE-MS, nadir was at 
week 13 (representing a change of approximately 
−50% from baseline; Table 1 and Figure 2E and 
F). In CLARITY Extension, nadir was at week 
24 (Figure 2E).
Cytotoxic T cells (CD8+). The response of CD8+ T 
cells showed some similarities to CD4+ T cells: a 
slow decline from baseline was followed by stabi-
lization with little sign of recovery until week 48. 
However, there was a notable difference com-
pared with CD4+ T cells, with the extent of reduc-
tion being smaller for CD8+ T cells; the IQRs for 
placebo and CT3.5 groups overlapped at the 
majority of timepoints. In CLARITY, the lowest 
numbers of CD8+ T cells was at week 48 (repre-
senting a change from baseline of approximately 
−30%). In CLARITY Extension and ORACLE-
MS, the nadir for CD8+ T cells was at week 24 
(representing changes of −36% to −48%, Table 1 
and Figure 2G and H).
Figure 1. Median absolute lymphocyte counts over time in patients treated with cladribine tablets 3.5 mg/kg or 
placebo in the first year of the ORACLE-MS study.
Lower and upper error bars indicate first and third quartile values. The lower limit of normal for lymphocyte counts is 
indicated by a horizontal line.
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Neutrophils and monocytes. In ORACLE-MS, 
median neutrophil counts showed a short-duration 
drop at week 2, but remained above the lower limit 
of normal (2.03 × 109 cells/l) and recovered quickly 
to baseline levels (Supplementary Figure 1A). 
Median monocyte counts showed no substantial 
reductions and remained close to baseline levels at 
all time points during ORACLE-MS (Supplemen-
tary Figure 1B). In CLARITY and CLARITY 
Extension, median neutrophil counts also remained 
within the normal range at all times up to and 
including week 48 (not shown). Monocyte counts 
for the CT3.5 and placebo groups showed compa-
rable median (0.4 × 109/l) and Q1; Q3 values (0.3; 
0.5 × 109/l) during CLARITY and CLARITY 
Extension, although there were differences in mini-
mum and maximum values (data not shown).
Extended analysis of T-lymphocyte subtypes in 
ORACLE-MS
Overall, reduction and recovery dynamics for 
CD4+ T-lymphocyte subtype counts in 
ORACLE-MS were broadly similar to those seen 
in total CD4+ T cells.
Naïve (CD4+CD45RA+) and memory (CD4+ 
CD45RO+) T-helper cells. Nadir was at week 13 
for CD4+CD45RA+ and CD4+CD45RO+ cells 
(Figure 3A and B), with naïve T-helper cells being 
slightly more affected than memory T helper 
(changes from week 0 of −62.6% and −50.8%, 
respectively).
Naïve (CD8+CD45RA+) and memory (CD8+CD4 
5RO+) cytotoxic T cells. Median counts of CD8+ 
CD45RA+ and CD8+CD45RO+ cells (Figure 
3C and D, respectively) reached nadir at week 13 
and week 48, respectively, with naïve cytotoxic T 
cells showing a greater reduction than memory 
cytotoxic T cells (changes from baseline of 
−65.2% and −34.8%, respectively). Naïve cyto-
toxic T-cell recovery was minimal, and memory 
cytotoxic T cells did not recover by week 48.
Central (CD4+RO+CCR7+) and effector (CD4+ 
RO+CCR7–) memory T cells. Median counts of 
CD4+RO+CCR7+ and CD4+RO+CCR7– cells 
reached nadir at week 24 (–62.6% change from 
week 0) and at week 13 (–53.5% change from 
baseline), respectively, and showed little sign of 
recovery by week 48 (Figure 4A and B). There 
were minor perturbations of the proportion of 
each subgroup from the starting median propor-
tions (Figure 4D and E). The proportion of 
CD4+RO+CCR7+ cells measured as a percent-
age of total CD4+ T cells was 25.0% at week 0. 
This proportion tended to decrease during the 
study, falling by 5.2% at week 5 and 9.3% at 
week 48. The proportion of CD4+RO+CCR7– 
cells as a percentage of total CD4+ T cells at 
week 0 was 31.0%. In contrast to 
CD4+RO+CCR7+ cells, the proportion of 
CD4+RO+CCR7– cells relative to total CD4+ T 
cells increased during the study, by 10.8% at 
week 13, and by 15.6% at week 48.
Th1-type helper T cells (CD4+CXCR3+). In 
CD4+CXCR3+ T cells, nadir was reached at 
week 24 (–50.8% change from baseline) and fol-
lowed by a slow return towards baseline (Figure 
4C). The proportion of CD4+CXCR3+ cells as a 
percentage of total CD4+ T cells was 34.9% at 
baseline, and showed only small changes over 
time (Figure 4F).
Naturally occurring T-regulatory cells (nTreg; CD4
+CD25+CD127–). Median CD4+CD25+CD127– 
cell counts reached nadir at week 24 (–47.3% 
change from baseline), and remained close to this 
level until week 48 (Figure 5A). The proportion 
of CD4+CD35+CD127– cells as a percentage of 
CD4+ T cells (10.1% at week 0) increased by 
9.2% and 33.9% at weeks 5 and 13, respectively, 
and then returned towards baseline at week 48 
(Figure 5D).
Naïve-like (CD4+CD25+CD127–RA[HI]+) and mem-
ory-like (CD4+CD25+CD127–RA–) nTreg cells.  
Median CD4+CD25+CD127–RA(HI)+ cell 
counts declined throughout the duration of the 
study period, and reached their lowest concentra-
tion at week 48 (–66.7% change from baseline; 
Figure 5B). Median CD4+CD25+CD127–RA– 
cell counts reached nadir at week 24 (–42.4% 
change from baseline), then increased slightly by 
week 48 (Figure 5C). The proportion of 
CD4+CD25+CD127–RA(HI)+ cells as a percent-
age of total nTreg cells measured at week 0 was 
27.0%. This decreased over time, with a reduc-
tion of 35.8% from week 0 to week 48 (Figure 
5E). In contrast, the proportion of memory-like 
CD4+CD25+CD127–RA–cells as a percentage of 
total nTreg cells at week 0 was 68.0%. This pro-
portion increased during the study from week 0 to 
11.2% at week 48 (Figure 5F).
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Discussion
Our findings show that following the first treat-
ment year for patients randomized to CT3.5 (the 
first of 2 years of treatment), the effects of CT3.5 
on B cells, T cells, NK cells, and innate immune 
system cells in patients with CIS are comparable 
with the effects observed in patients with estab-
lished RRMS. This immune cell analysis com-
prised data from only the first year of a total 
CT3.5 treatment. It is important to note that 
CT1.75 is not an indicated dose, and results from 
analysis of 1-year data should not be interpreted 
as any indication of a 1-year clinical benefit.
Across three studies, we observed a large reduc-
tion in B cells (approximately 80% at nadir, 
Figure 2C and D), a moderate reduction in T 
cells (CD4+ approximately 50%, Figure 2E and 
F; and CD8+ approximately 40% at nadir, 
Figure 2G and H), and smaller reductions in 
NK cells (between 30% and 44% at nadir; 
Figure 2A and B). Innate immune system cells 
were largely unaffected by treatment with CT3.5 
(Supplementary Figure 1): neutrophil counts 
remained within the lower limit of normal and 
had recovered by week 5. Monocyte counts 
were largely unaffected.
The dynamics of lymphocyte reduction demon-
strated that CD16+/56+ NK cells were the most 
rapid to reach nadir, doing so by week 5. This 
may, of course, be attributable to requiring less 
time to reach a modest nadir, as discussed above, 
with other subsets requiring more time to reach 
deeper nadirs. Both CD19+ B cells and CD4+ 
T-helper cells reached nadir at week 13, with a 
O Stuve, PS Sorensen et al.
journals.sagepub.com/home/tan 9
Figure 2. Median counts over time in patients treated with cladribine tablets 3.5 mg/kg or placebo for 
natural killer cells (CD16+/CD56)+ in (A) CLARITY and CLARITY Extension and (B) ORACLE-MS; for B cells 
(CD19+) in (C) CLARITY and CLARITY Extension and (D) ORACLE-MS; for T-helper cells (CD4+) in (E) CLARITY 
and CLARITY Extension and (F) ORACLE-MS; and for T-cytotoxic cells (CD8+) (G) in CLARITY and CLARITY 
Extension and (H) ORACLE-MS.
Lower and upper error bars indicate first and third quartile values. The value shown on the figure indicates the percentage 
change from baseline at nadir in patients treated with cladribine tablets 3.5 mg/kg. CLARITY Extension patients are those 
who received placebo in CLARITY.
Figure 2. (Continued)
particularly profound reduction of the CD19+ B 
cells (changes from baseline: −82.2%). CD8+ 
cytotoxic T cells were the slowest to reach nadir.
The dynamics of reconstitution were similar to 
the observed patterns for reduction, with recov-
ery towards baseline levels by week 24 for 
CD16+/56+ NK cells and by week 48 for CD19+ 
B cells (Table 1). Given the small reduction for 
the CD16+/CD56+ NK cells, a relatively quick 
recovery may have been expected. More note-
worthy is the speed of recovery towards baseline 
for the CD19+ B cells given their large reduction 
from baseline. The CD4+ and CD8+ T cells had 
a more gradual recovery (minimal recovery at 
week 48; Figure 2). This is perhaps unsurprising, 
given the slow rate of reduction of cell numbers 
leading to nadir. Retreatment guidelines based 
on lymphocyte counts were applied during the 
conduct of ORACLE-MS and are included in 
Therapeutic Advances in Neurological Disorders 12
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the approved prescribing information for cladrib-
ine tablets.
The effect of the first year of treatment with 
CT3.5 on proportions of lymphocyte subtypes 
(Figures 4D–F and 5D–F) was of interest in this 
study because homeostasis and function of 
immune cells is dependent upon their relative 
ratios. Since the majority of autoreactive T cells 
in MS appear to be memory CD4+ T cells,22 with 
a large proportion derived from CCR7+ central 
memory cells,23 the effects of CT3.5 on these cell 
populations was of high interest. In ORACLE-MS, 
counts of both memory and effector CD4+ T 
lymphocytes decreased after treatment with 
CT3.5 (63% and 54%, respectively, at nadir) and 
this was accompanied by changes in the ratio of 
these subtypes (Figure 4D and E). Interestingly, 
CD4+ central memory and effector memory T 
cells displayed quite different reconstitution 
dynamics, with the former remaining lower at 48 
weeks than at baseline but with effector memory 
T cells being ~16% higher at week 48 than at 
baseline.
The effect of treatment on subtypes and ratios of 
nTregs was also studied as these cells have a 
strong suppressive effect on T cells and myeloid 
Figure 3. Median counts over time for T-cell subtypes: (A) naïve T-helper cells (CD4+CD45RA+); (B) memory 
T-helper cells (CD4+CD45RO+); (C) naïve cytotoxic T cells (CD8+CD45RA+); and (D) memory cytotoxic T cells 
(CD8+CD45RO+) in the ORACLE-MS study.
Lower and upper error bars indicate first and third quartile values. The value shown on the figure indicates the percentage 
change from baseline at nadir in patients treated with cladribine tablets 3.5 mg/kg.
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cells.24,25 At week 48, nTreg counts had decreased 
from baseline by nearly half. Naïve-like nTregs 
had a larger reduction than memory-like nTregs 
(Figure 5A–C). Considered together with the 
effects on CD4+ and cytotoxic CD8+ T cells 
(Figure 3A and B), naïve-like nTregs may be 
more sensitive to cladribine than memory-like 
nTregs. The larger decrease in naïve-like nTregs 
was accompanied by a reduction in their propor-
tion at week 48 compared with week 0 (~36%; 
Figure 5E). In contrast, the proportion of mem-
ory-like nTregs increased at week 48 compared 
with week 0 (~11%; Figure 5F). It remains to be 
determined whether these findings are confined 
to the peripheral immune compartment or affects 
both peripheral cells and immune cells resident in 
the central nervous system (CNS). Further work 
is ongoing to characterize the effects of treatment 
with CT3.5 on FOX P3+ nTregs, and also nTreg 
to T-effector cell ratios, which may be important 
immunological changes in MS and therefore may 
lead to a better understanding of the effects of 
DMTs.26,27
A key differentiator of CT3.5 is the discontinuous 
nature of peripheral lymphocyte reductions. In 
ORACLE-MS, ALC and CD19+ B-cell counts 
were recovering towards baseline levels at week 48. 
Findings from longer-term studies (using data from 
CLARITY and CLARITY Extension) demonstrate 
that ALC and CD19+ B-cell counts recover and sta-
bilize.28 It should be noted that other B-cell subtypes 
were not analyzed, so it is not possible to comment 
on their reduction and repopulation dynamics. In 
contrast, reductions in T-cell subsets were modest in 
size but had a more gradual recovery up to week 48 
of treatment. The first year of treatment with CT3.5 
did not appear to be associated with an above-base-
line rise in B or T cells following the initial reduction 
phase by week 48. Immune dysfunction associated 
with homeostatic proliferation after treatment with 
lymphocyte-depleting therapies (e.g. alemtuzumab 
and rabbit antithymocyte globulin) has been shown 
in transplant and MS patients. In this context, the 
skewing of repopulating lymphocytes towards a 
more memory-type phenotype has been described, 
but a deeper understanding of the underlying biol-
ogy is still warranted.29–32 Homeostatic proliferation 
from the peripheral pool may predispose to 
autoimmunity.31
There has been considerable debate about the 
relative importance of B cells and B-cell subsets 
in the pathogenesis and treatment of RRMS.16,17 
There are studies indicating an important patho-
logical role for memory B cells in RRMS and, 
more recently, in primary progressive MS.17,33,34 
However, reduction of B cells alone may be insuf-
ficient to explain efficacy in RRMS, as rituximab 
treatment significantly decreases counts of both B 
and T cells and attenuates proinflammatory 
responses, suggesting that reduction of both cell 
types may be important.35,36 A recent publication 
by Jelcic et  al. suggested that memory, notably 
unswitched memory, B cells directly promote 
autoproliferation and activation of ‘brain-hom-
ing’ CD4+ T cells.37 The autoproliferating CD4+ 
T cells have a strong affinity for some antigens 
expressed by the brain or by B cells.37 If corrobo-
rated, these findings may provide further ration-
ale for drugs that target B cells, as they demonstrate 
a complex and closely intertwined relationship 
between B cells and T cells in MS pathogenesis.
Alemtuzumab markedly decreases B-cell and 
CD4+ and CD8+ lymphocyte counts and has 
some effects on NK cells. The magnitude of effect 
of alemtuzumab and cladribine were compared 
by Baker et al. and found to be comparable with 
respect to B-cell reduction; T-cell reduction with 
cladribine was more modest than was shown for 
alemtuzumab.16 Fingolimod treatment reduces 
total B-cell counts but increases the relative pro-
portion of naïve B cells,38 with similar effects (an 
increase in transitional B cells) reported for 
patients treated with interferon-β.39 Furthermore, 
the potentially complex role of B cells in RRMS is 
highlighted by studies with atacicept, a fusion 
protein with potent B-cell suppressive effects. In 
patients with RRMS, atacicept reduced B-cell 
counts but increased relapse activity compared 
with placebo.40
In the present analysis, following treatment with 
CT3.5, B cells showed fast (approximately 70% 
reduction at week 5) and large reductions (>80% 
reduction at the week 13 nadir) compared with T 
cells (approximately 50% reduction at week 5). 
The rapid recovery of B cells should be consid-
ered in the context of the durable and relatively 
rapid clinical effect of CT3.5 (in CLARITY, T1 
Gd+ MRI activity was undetectable at week 24 in 
patients treated with CT3.5).11 One question is 
how CT3.5 produces durable clinical effect over 
several years, after two short treatment periods in 
Year 1 and Year 2. In addition, how the changed 
proportion of memory-like Tregs may contribute 
to this long-term efficacy observed in studies. 
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How this may affect B cells, T-effector cells and 
other T-cell subtypes is uncertain and will be key 
areas for future research. A general limitation of 
immunophenotyping studies after treatment with 
lymphocyte-depleting therapies is the fact that 
only blood has been analyzed in most MS trials, 
and the level of depletion and order of repopula-
tion in primary and secondary lymphoid organs 
or cerebrospinal fluid is still unknown. Fully char-
acterizing the reconstitution of the adaptive 
immune system after treatment with CT3.5 may 
require further functional and qualitative analysis 
of study of lymphocytes subsets.
The low level of opportunistic infections in the 
clinical development program is evidence of 
immune system competence following CT3.5 
treatment. Lymphocyte recovery began soon after 
treatment, which may, in part, account for the low 
frequency of severe lymphopenia associated with 
CT3.5.13 Data from CLARITY and CLARITY 
Extension also show that no cases of Common 
Terminology Criteria for Adverse Events 
(CTCAE) Grade 4 lymphocyte counts were pre-
sent at the end of any treatment year in patients 
treated with CT3.5 according to treatment guide-
lines.41 Consistent with this, neutrophil recovery 
in ORACLE-MS was also rapid, with a low fre-
quency of severe neutropenia (Supplementary 
Figure 2) and no cases of CTCAE Grade 4 (seri-
ous) neutropenia at any time.
This study was limited by its exploratory nature. No 
statistical testing for multiplicity was carried out and 
the outcomes reported here should be considered as 
suggestive, highlighting future areas for research. 
Furthermore, measurements of lymphocyte counts 
were made using peripheral blood only. Cladribine 
is highly distributed in tissue shortly after adminis-
tration, and the possible effects of treatment on lym-
phocytes within tissues such as the CNS have not 
been determined. In addition, assessment of 
B-lymphocyte subsets, particularly memory sub-
sets, was not included in these analyses.
Conclusion
In patients with CIS and RRMS, treatment with 
cladribine tablets in the first year led to substantial 
but transient reductions in CD19+ B cells and 
smaller but more long-lasting reductions in 
T-lymphocyte subtypes followed by gradual recov-
ery. The relative selectivity of CT3.5 for lympho-
cytes was demonstrated by the lack of effect on 
neutrophils and monocytes, and a moderate and 
transient effect on NK cells. In the extended analy-
sis of patients from the ORACLE-MS study, there 
were alterations in the proportions of some CD4+ 
T-cell subtypes, relative to the overall CD4+ T-cell 
population, with small decreases in the proportions 
of central memory T cells. In contrast, memory-
like Treg cells appeared to increase as a proportion 
of the T-lymphocyte pool by week 48. Furthermore, 
nTreg cells increased as a proportion of CD4+ 
cells, before returning to baseline levels by week 48. 
However, the changes in nTregs were underpinned 
by decreasing proportions of naïve-like nTreg cells 
in parallel with increased proportions of memory-
like nTreg cells.
It must be noted that these lymphocyte population 
dynamics are not yet known following the second 
year of treatment, as approved, and contributions 
of such changes to a clinical therapeutic effect are 
currently unknown. This immune cell analysis 
comprised data from only the first year of a total 
CT3.5 treatment. It is important to note that 
CT1.75 is not an indicated dose, and results from 
analysis of 1-year data should not be interpreted as 
any indication of a 1-year clinical benefit.
These findings provide further insights into how 
CT3.5 may selectively target and reduce T and B 
lymphocytes with transient effects on NK cells 
and minimal innate immune system impact, as 
part of a unique approach to IRT in MS.
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